This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cicin-Sain, L.
Right arrow Articles by Koszinowski, U. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cicin-Sain, L.
Right arrow Articles by Koszinowski, U. H.

 Previous Article  |  Next Article 

Journal of Virology, December 2007, p. 13825-13834, Vol. 81, No. 24
0022-538X/07/$08.00+0     doi:10.1128/JVI.01911-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine Strategy{triangledown}

Luka Cicin-Sain,1,2* Ivan Bubic,3 Margit Schnee,2 Zsolt Ruzsics,2 Christian Mohr,2 Stipan Jonjic,3 and Ulrich H. Koszinowski2

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon 97006,1 Max von Pettenkofer Institute, Ludwig Maximilians-University, 30886 Munich, Germany,2 Department of Histology and Embryology, Medical Faculty, University of Rijeka, 51000 Rijeka, Croatia3

Received 31 August 2007/ Accepted 20 September 2007

Human cytomegalovirus (CMV), a ubiquitous human pathogen, is a leading cause of congenital infections and represents a serious health risk for the immunosuppressed patient. A vaccine against CMV is currently not available. CMV is characterized by its large genome and by multiple genes modulating the immunity of the host, which cluster predominantly at genome termini. Here, we tested whether the deletion of gene blocks rich in immunomodulatory genes could be used as a novel concept in the generation of immunogenic but avirulent, herpesvirus vaccines. To generate an experimental CMV vaccine, we selectively deleted 32 genes from the mouse cytomegalovirus (MCMV) genome. The resulting mutant grew to titers similar to that of wild-type MCMV in vitro. In vivo, the mutant was 10,000-fold attenuated and well tolerated, even by highly susceptible mice deficient for B, T, and NK cells or for the interferon type I receptor. Equally relevant for safety concerns, immune suppression did not lead to the mutant's reactivation from latency. Immunization with the replication-competent mutant, but not with inactivated virus, resulted in protective immunity, which increased over time. Vaccination induced MCMV-specific antibodies and a strong T-cell response. We propose that a targeted and rational approach can improve future herpesvirus vaccines and vaccine vectors.

* Corresponding author. Mailing address: Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 NW 185th Ave., Beaverton, OR 97006. Phone: (503) 418-2760. Fax: (503) 418-2764. E-mail: cicinsai{at}ohsu.edu

{triangledown} Published ahead of print on 3 October 2007.

Journal of Virology, December 2007, p. 13825-13834, Vol. 81, No. 24
0022-538X/07/$08.00+0     doi:10.1128/JVI.01911-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»